Needham Maintains Buy on Taysha Gene Therapies, Lowers Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum maintains a Buy rating on Taysha Gene Therapies (NASDAQ:TSHA) but lowers the price target from $7 to $6.

August 12, 2024 | 5:42 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Needham analyst Gil Blum maintains a Buy rating on Taysha Gene Therapies but lowers the price target from $7 to $6.
The Buy rating suggests continued confidence in the company's prospects, but the lowered price target indicates tempered expectations. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100